Scott Juang’s Post

This is a small but meaningful step toward augmenting human creativity and accelerate innovation in life sciences.

Future is GPU-optimized

Big day today - NVIDIA is open-sourcing the BioNeMo Framework, a toolkit of programming resources, libraries, and AI models designed for drug discovery. This release equips academic labs and biotech companies with tools for protein design, small molecule generation, and even custom model development. Built with GPU optimization in mind, BioNeMo is made to speed biochem predictive modeling, and we think this is an impactful step ahead in development of computer-aided drug discovery. https://lnkd.in/gQuxGyc5

NVIDIA Open-Sources BioNeMo Framework for AI-Driven Drug Discovery In a significant step forward for computer-aided discovery of biomolecules, NVIDIA has open-sourced its BioNeMo Framework, a comprehensive toolkit of programming resources, libraries, and AI models designed specifically for drug discovery. This move empowers academic labs and biotech companies with the tools necessary for protein design, small molecule generation, and custom model development. By leveraging GPU optimization, BioNeMo is poised to accelerate biochemical predictive modeling, paving the way for groundbreaking advancements in the field. The BioNeMo ecosystem comprises a framework of programming tools and packages offering access to optimized, pre-trained biomolecular models and workflows, as well as easy-to-use inference microservices with built-in API endpoints. Notable companies such as Amgen, Cognizant, and Cadence have already harnessed the power of BioNeMo to enhance biologics discovery and development, accelerate drug discovery, and shorten time to trusted results in therapeutic design. #quantum #quantumcomputing #technology https://lnkd.in/eAMJm-rD

Amgen will build AI models trained to analyze one of the world’s largest human datasets on an #NVIDIADGX SuperPOD, which will feature 31 NVIDIA DGX H100 nodes totaling 248 H100 Tensor Core GPUs, to advance drug discovery. Learn more now. #GenerativeAI #DataCenter

🚀 Denmark's First AI Supercomputer is Now Operational! 🇩🇰 Exciting times for the Nordic tech ecosystem as Denmark unveils its first AI supercomputer, thanks to the Novo Nordisk Foundation. This state-of-the-art infrastructure will transform healthtech innovation. Among the first pilot projects, the supercomputer will power: 1️⃣ “Building an AI Care Companion with Large Video Pretraining” – Aimed at developing AI solutions to assist in patient care, enhancing diagnostics, and improving patient outcomes. This project is a collaboration between Teton and the University of Copenhagen (Københavns Universitet). 2️⃣ “Multimodal Genomic Foundation Model” – Led by the University of Copenhagen (Københavns Universitet), this project focuses on integrating various genomic data to create a robust foundation model, unlocking new potentials for precision medicine and targeted treatments. Looking forward to the impact these projects will have on the future of healthcare and patient care! https://lnkd.in/ek3hxxFT

"Revolutionizing Drug Discovery with NVIDIA BioNeMo: Accelerating Cost Efficiency and Time to Market" I'm excited to share NVIDIA's recent announcement that could redefine how we approach drug discovery and molecular design. The open-sourced BioNeMo Framework leverages generative AI and supercomputing to empower researchers and businesses. 🌐 Explore the official press release here 👉 https://lnkd.in/gjZh8RW4 📂 GitHub Repository 👉 https://lnkd.in/gDq4QaxB At its core, BioNeMo uses scalable, end-to-end AI models to streamline R&D processes. Tasks such as molecular screening and structural predictions, which traditionally take months, can now be completed within weeks. This translates into significant cost reductions and faster time to market. Critical Benefits of BioNeMo for Businesses Reduced Costs Minimizes experimental failures, enabling up to 30% reduction in research expenses. Example: Virtual screening processes are significantly optimized, cutting evaluation times for target candidates and redirecting resources toward high-value initiatives. Accelerated Time to Market Speeds up molecule design and predictions, shortening drug development timelines. Competitive Edge: Early market entry strengthens market positioning and accelerates revenue generation. Scalable Infrastructure With NVIDIA NIM™ microservices (Learn More), businesses can deploy flexible AI inference pipelines across on-premises or cloud environments. Adaptability: Suitable for research labs of any size, from small biotech startups to large pharmaceutical enterprises. Proven Track Record: Trusted by 200+ Organizations Over 200 organizations, including leading pharmaceutical companies, tech-bio firms, and startups, have already integrated BioNeMo into their workflows. Supported by system integrators like AWS and Deloitte, the framework scales to meet the diverse needs of modern drug discovery teams. Why This Matters for Business Leaders "BioNeMo is more than a research tool—it's a strategic platform for driving cost savings, risk reduction, and accelerated revenue generation. By adopting this framework, organizations can establish competitive advantages in a rapidly evolving industry and unlock the full potential of AI-driven drug discovery." Explore how BioNeMo can benefit your organization: GitHub Repository: https://lnkd.in/gDq4QaxB Official Information: https://lnkd.in/gjZh8RW4 Discover how BioNeMo can transform your R&D pipeline and secure a competitive edge in the biotech and pharmaceutical industries. Join us in accelerating the future of drug discovery! #GenerativeAI #DrugDiscovery #AIinHealthcare #BusinessInnovation #DigitalBiology #LifeSciences #NVIDIA

Montai Therapeutics is leveraging NVIDIA's BioNeMo DiffDock NIM to develop an advanced multimodal #AI #drugdiscovery platform, incorporating a library of Anthromolecule chemistry. This approach has led to the creation of a highly accurate and efficient model, capable of generating 40 poses per ligand using 8xA100 GPUs, with a processing speed of 0.76 seconds per ligand. Read more on our latest technical blog. #healthcare

Montai Therapeutics is leveraging NVIDIA's BioNeMo DiffDock NIM to develop an advanced multimodal #AI #drugdiscovery platform, incorporating a library of Anthromolecule chemistry. This approach has led to the creation of a highly accurate and efficient model, capable of generating 40 poses per ligand using 8xA100 GPUs, with a processing speed of 0.76 seconds per ligand. Read more on our latest technical blog. #healthcare

Montai Therapeutics is leveraging NVIDIA's BioNeMo DiffDock NIM to develop an advanced multimodal #AI #drugdiscovery platform, incorporating a library of Anthromolecule chemistry. This approach has led to the creation of a highly accurate and efficient model, capable of generating 40 poses per ligand using 8xA100 GPUs, with a processing speed of 0.76 seconds per ligand. Read more on our latest technical blog. #healthcare